Distribution, Chemotherapy Use, and Outcome of the 21-Gene Recurrence Score Between Chinese and White breast Cancer in the United States

Li, Guanqiao; Yao, Jia; Zhou, Ping; Chen, Dan-Xia; Lian, Chen-Lu; Yang, Shi‐Ping; Huang, Caihong; Wu, San‐Gang

doi:10.1016/j.clbc.2021.11.003

Cited by 4 publications

(3 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Only 98 patients who had N1 diseases limited the study to the general population. In our previous study, we found similar distribution, chemotherapy use, and prognostic prediction of the 21-gene RS between Chinese and white American BC patients ( 25 ). For Chinese female patients, approximately one-quarter suffered from N1 disease at the time of BC diagnosis ( 26 ).…”

Section: Discussionmentioning

confidence: 61%

Impact of the 21-gene expression assay on treatment decisions and clinical outcomes in breast cancer with one to three positive lymph nodes

Xie²,

Wu³

et al. 2023

Front. Endocrinol.

Self Cite

View full text Add to dashboard Cite

BackgroundTo assess the practice patterns of the recurrence score (RS) based on the 21-gene expression assay on adjuvant chemotherapy recommendations and survival outcomes in estrogen receptor-positive (ER+)/HER2- breast cancer (BC) with one to three positive lymph nodes (N1).MethodsWe included patients with T1-2N1M0 and ER+/HER2- BC diagnosed between 2010 and 2015 in the Surveillance, Epidemiology, and End Results Oncotype DX Database. Breast cancer-specific survival (BCSS) and overall survival (OS) were assessed.ResultsWe included 35,137 patients in this study. There were 21.2% of patients who had RS testing in 2010, which was significantly increased to 36.8% in 2015 (P < 0.001). Performance of the 21-gene testing was associated with older age, lower tumor grade, T1 stage, lower number of positive lymph nodes, and progesterone receptor-positive disease (all P < 0.05). In those without 21-gene testing, age was the main factor significantly related to the receipt of chemotherapy, whereas RS was the main factor significantly related to chemotherapy receipt in those with 21-gene testing. The probability of chemotherapy receipt in those without 21-gene testing was 64.1% and was decreased to 30.8% in those with 21-gene testing. On multivariate prognostic analysis, the performance of 21-gene testing was associated with better BCSS (P < 0.001) and OS (P < 0.001) compared with those without 21-gene testing. Similar results were found after propensity score matching.ConclusionsThe 21-gene expression assay is frequently and increasingly used for chemotherapy decision-making in ER+/HER2- BC with N1 disease. Performance of the 21-gene testing is associated with improved survival outcomes. Our study supports the routine use of 21-gene testing in the clinical practice of this population.

show abstract

Section: Discussionmentioning

confidence: 61%

Impact of the 21-gene expression assay on treatment decisions and clinical outcomes in breast cancer with one to three positive lymph nodes

Xie²,

Wu³

et al. 2023

Front. Endocrinol.

Self Cite

View full text Add to dashboard Cite

show abstract

“…Five studies based on the SEER database and one based on the NCDB database have since explored racial/ethnic differences in RS results and clinical outcomes 89–94 . These included between ~67 000 and 88 500 patients focusing on non‐Hispanic White (White), non‐Hispanic Black (Black), and Chinese American patients.…”

Section: Resultsmentioning

confidence: 99%

“…88 Five studies based on the SEER database and one based on the NCDB database have since explored racial/ethnic differences in RS results and clinical outcomes. [89][90][91][92][93][94] These included between ~67 000 and 88 500 patients focusing on non-Hispanic White (White), non-Hispanic Black (Black), and Chinese American patients. There was no ethnic group for which the RS result was found not to be prognostic, although in one study by Jung 90 and colleagues the ability of the assay to predict CT benefit was not confirmed in non-White women.…”

Section: Mammaprint ®mentioning

confidence: 99%

Selecting postoperative adjuvant systemic therapy for early‐stage breast cancer: An updated assessment and systematic review of leading commercially available gene expression assays

Hyams,

Bareket‐Samish,

Rocha

et al. 2024

Journal of Surgical Oncology

View full text Add to dashboard Cite

Gene expression assays (GEAs) can guide treatment for early‐stage breast cancer. Several large prospective randomized clinical trials, and numerous additional studies, now provide new information for selecting an appropriate GEA. This systematic review builds upon prior reviews, with a focus on five widely commercialized GEAs (Breast Cancer Index®, EndoPredict®, MammaPrint®, Oncotype DX®, and Prosigna®). The comprehensive dataset available provides a contemporary opportunity to assess each GEA's utility as a prognosticator and/or predictor of adjuvant therapy benefit.

show abstract

Nomogram Update to Predict the High Genomic Risk Breast Cancer by Different Races

Wu,

2024

Clinical Breast Cancer

View full text Add to dashboard Cite

Distribution, Chemotherapy Use, and Outcome of the 21-Gene Recurrence Score Between Chinese and White breast Cancer in the United States

Cited by 4 publications

References 25 publications

Impact of the 21-gene expression assay on treatment decisions and clinical outcomes in breast cancer with one to three positive lymph nodes

Impact of the 21-gene expression assay on treatment decisions and clinical outcomes in breast cancer with one to three positive lymph nodes

Selecting postoperative adjuvant systemic therapy for early‐stage breast cancer: An updated assessment and systematic review of leading commercially available gene expression assays

Nomogram Update to Predict the High Genomic Risk Breast Cancer by Different Races

Contact Info

Product

Resources

About